of this current report on Form 8-K (including the accompanying Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing, except as expressly incorporated…

Entry into a Material Definitive Agreement. On May 29, 2026, Solana Company (the “Company”) entered into an Amended and Restated Sales Agreement (the “Sales Agreement”) with Clear Street LLC (“Clear Street”) and Maxim Group LLC (“Maxim”) (each, an “Agent,” and, together, the “Agents”), as co-sales agents, pursuant to which the Company may offer and sell shares of the Company’s Class A common stock, par value $0.001 per share (the “Shares”) from time to time in connection with its existing “at…

of this Current Report on Form 8-K (including the accompanying Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, except as expressly incorporated…

by reference. The Put Options (as defined below) have not been registered under the Securities Act of 1933, as amended (the “Securities Act”) or the securities laws of any state, and are being offered and sold in reliance on the exemption from registration under the Securities Act, afforded by Section 4(a)(2) and/or Rule 506 promulgated thereunder.

Other Events. Registered Direct Offering On April 27, 2026, Solana Company (the “Company”) entered into securities purchase agreements (collectively, the “RDO Purchase Agreements”) with the purchasers named therein (the “Purchasers”), pursuant to which (i) the Company issued and sold to the Purchasers, in a registered direct offering (the “Registered Direct Offering”), 3,076,922 shares (the “Shares”) of the Company’s Class A common stock, $0.001 par value per share (the “Common Stock”). The o…

Director — Sherrie Perkins and Paul Buckman: Sherrie Perkins and Paul Buckman decided not to stand for re-election as directors.

Chief Medical Officer — Antonella Favit-Van Pelt, MD, PhD: Dr. Favit-Van Pelt mutually agreed to separate from the Company and resign as Chief Medical Officer.

Chief Operating Officer and Deputy Chief Financial Officer — Agustina “Madelene” Gani Tjandrasuwita: Solana Company hired a new Chief Operating Officer and Deputy Chief Financial Officer from an external company.

of this Current Report on Form 8-K (including the accompanying Exhibit 99.1 hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filings, except as expressly incorporated…

Results of Operations and Financial Condition. ​ On November 18, 2025, Solana Company (formerly known as Helius Medical Technologies, Inc.) (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025, a business update, and information regarding a conference call to discuss these financial results and recent corporate highlights. A copy of this press release is furnished herewith as Exhibit 99.1 to this Current Report and is incorporated he…

Regulation FD Disclosure. ​ On November 5, 2025, Solana Company (formerly known as Helius Medical Technologies, Inc.) (the “Company”) issued a press release announcing that its board of directors approved a stock repurchase plan to acquire up to $100 million of the Company’s outstanding Class A common stock, $0.001 par value per share. A copy of the press release is attached hereto as Exhibit 99.2 and incorporated herein by reference. ​ Information contained on or accessible through any websi…

Director — Jeffrey S. Mathiesen: Mr. Mathiesen resigned from the Board of Directors.

Other Events. ​ On November 3, 2025, the Company’s Board authorized a stock repurchase program for the purchase of up to $100 million of the Company’s outstanding Common Stock. Repurchases of Common Stock may be made in the open market (including through Rule 10b-18 compliant transactions), in privately negotiated transactions, in block trades, through one or more accelerated share repurchase transactions, through one or more trading plans intended to comply with Rule 10b5-1, through tender o…

Changes in Registrant’s Certifying Accountant. ​ (a) Resignation of Previous Independent Registered Public Accounting Firm ​ On October 15, 2025, the Audit Committee (the “Committee”) of the Board of Directors of Solana Corporation (formerly known as Helius Medical Technologies, Inc.) (the “Company”) received the resignation of Baker Tilly US, LLP (“Baker Tilly”) as the Company’s independent registered public accounting firm, effective immediately. The Committee accepted Baker Tilly’s resigna…

The company provided one-time cash bonuses to the CEO and CFO in exchange for waiving certain benefits.

Executive Chairman of the Board — Joseph Chee: The appointment of Joseph Chee as Executive Chairman of the Board represents a significant external hire and an increase in board size.

Entry into a Material Definitive Agreement As previously disclosed, on September 15, 2025, Helius Medical Technologies, Inc. (the “Company”) entered into subscription agreements (the “Cash Subscription Agreements”) with certain accredited investors (the “Cash Purchasers”) pursuant to which the Company, in a private placement (the “Cash Offering”), agreed to issue and sell to the Cash Purchasers an aggregate of (i) 37,825,277 shares of Class A common stock of the Company, par value $0.001 per…

to this Current Report, and in Exhibit 99.1 furnished herewith, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall such information be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such a filing. Forward-Looking Statements This Current Report co…

Unregistered Sales of Equity Securities The disclosure required by this Item is included in

Entry into a Material Definitive Agreement. On September 15, 2025, Helius Medical Technologies, Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Clear Street LLC (“Clear Street”) and Maxim Group LLC (“Maxim”) (each, an “Agent,” and, together, the “Agents”), as co-sales agents, pursuant to which the Company may offer and sell shares of the Company’s Class A common stock, par value $0.001 per share (the “Shares”) from time to time having an aggregate sales price…

Unregistered Sales of Equity Securities The disclosure required by this Item is included in

Regulation FD Disclosure. Press Release on Announcing the Offering On September 15, 2025, the Company issued a press release announcing the signing of the Purchase Agreements and pricing of the Offerings and estimated aggregate gross proceeds of approximately $500 million in cash, before deducting placement agent fees and other offering expenses, to implement a SOL treasury strategy. A copy of the press release is included as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated…

Entry into a Material Definitive Agreement. Securities Purchase Agreements On September 15, 2025, Helius Medical Technologies, Inc. (the “ Company ”) entered into securities purchase agreements (the “ Cash Securities Purchase Agreements ”) with certain accredited investors (the “ Cash Purchasers ”) pursuant to which the Company agreed to sell and issue to the Cash Purchasers in a private placement offering (the “ Cash Offering ”) an aggregate offering of (i) either shares (the “ Cash Shares ”…

Other Events. ​ On July 21, 2025, Helius Medical Technologies, Inc. (the “Company”) announced the positive outcome of the Portable Neuromodulation Stimulator (“PoNS”) Stroke Registrational Program (“SRP”) and planned upcoming FDA submission seeking an indication for gait and balance deficit in patients with chronic symptoms of stroke under the current Breakthrough Device Designation. The key primary outcomes from the SRP indicate that (i) a double-blind randomized clinical trial met the prima…

Other Events. As previously disclosed, on June 23, 2023, Helius Medical Technologies, Inc., (the “Company”), entered into a Sales Agreement (the “Sales Agreement”) with Roth Capital Partners, LLC (the “Agent”), as sales agent, pursuant to which the Company may offer and sell shares of the Company’s common stock, par value $0.001 per share (the “Shares”). On July 7, 2025, the Company filed an updated Prospectus Supplement (the “Prospectus”) for the offer and sale of up to $25 million of Shares…